

SDI FINAL EVALUATION FORM 1.1

SCIENCEDOMAIN international
www.sciencedomain.org

**PART 1:**

Journal Name:	<u>Journal of Cancer and Tumor International</u>
Manuscript Number:	Ms_JCTI_33794
Title of the Manuscript:	Induction Chemotherapy followed by Concurrent Chemo-Conformal Radiation Therapy in Locally Advanced Nasopharyngeal Carcinoma
Type of Article:	Original Research Article

**PART 2:**

FINAL EVALUATOR'S comments on revised paper (if any)	Authors' response to final evaluator's comments
Authors have replied that "keratinising squamous cell carcinoma was not excluded from the trial , it was of the eligibility criteria of our study but 100 % of cases of locally advanced NPC presented to us were undifferentiated carcinoma.", however it is clearly written in the manuscript that "Exclusion criteria included WHO type I NPC (keratinizing SCC)". It's ok if all the patients were of undifferentiated type, but then, the histopathological type should not be written in inclusion/exclusion criteria. Author's reply "During this period , TPF regimen was tried 1st on locally advanced Head and neck cancer but not on NPC and the encouraging results obtained was the rational for its trial on locally advanced NPC." This statement must be true at the time of conducting this trial, but is not true at the present time as there are phase III trials showing the benefit of NACT in advanced NPC. So this statement needs to be revised. Author's response "The average dose delivered is 70 Gy .There are different doses prescribed due to the presence of different targets . The GTV P70 received 60 Gy followed by 10-14 Gy (not 10 Gy) ie the total dose to this target is 70 -74 Gy And the CTV LN received 60 GY+6-10 Gy (i e the total dose from 66-70GY)" There should be a table describing the different doses delivered to the patients, that is how many patients received 70 Gy or 72 Gy and so on.	I meant (non-keratinizing squamous cell carcinoma) , it is one of the eligibility criteria in our study but by mistake it was written keratinizing squamous cell carcinoma which has been excluded from our trial as it is only common in the US and it is known to be less radiosensitive than the other 2 types However , I agree with you , that the histopathology not recommended to be written in the inclusion/exclusion criteria. I have done edition for this part This statement has been edited and the results of recently published phase III trials have been incorporated within the paper. I have added a table describing the different targets and doses prescribed to them.